Currency In USD
| Previous Close | 1.74 |
| Open | 1.72 |
| Day High | 1.72 |
| Day Low | 1.6 |
| 52-Week High | 3.04 |
| 52-Week Low | 0.44 |
| Volume | 285,093 |
| Average Volume | 720,193 |
| Market Cap | 296.96M |
| PE | -1.93 |
| EPS | -0.85 |
| Moving Average 50 Days | 1.66 |
| Moving Average 200 Days | 2.07 |
| Change | -0.1 |
Century Therapeutics to Participate in Upcoming Investor Conferences in March
GlobeNewswire Inc.
Feb 25, 2026 1:00 PM GMT
PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes,
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
GlobeNewswire Inc.
Dec 09, 2025 1:00 PM GMT
PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced